The traditional management of MTC still relies on the serial measurement of calcitonin (CT) and carcinoembryonic antigen (CEA) and their doubling times, whose increase suggests disease progression and/or metastatic spread (1). This evidence concerns the gene CEACAM5 and medullary thyroid gland carcinoma.